Your search matched 240 results
We’ve recapped Scott Gottlieb’s eventful penultimate week at the FDA in this week’s edition of The Week That Was.
This week’s edition of The Week That Was looks at how not to spin a poor earnings report.
We’ve analyzed their progress in this week’s issue of The Week That Was.
In this week’s edition of The Week That Was, we explain one way they can communicate value.
Check out the Week That Was for the answer.
A busy week in Washington | Blog
So, a lot happened in Washington this week… which we won’t be commenting on!
Read this and more in this week's TWTW!
This week’s edition of The Week That Was takes a look and provides insights from a new ICER report.
Take a look at the latest insights in this week’s issue of The Week That Was.
No matter whether you were the lone staffer in your office or relaxing on a beach somewhere this past week, we’ve got the run down on the latest healthcare headlines—the good, the bad and the ugly—to help you get you back up to speed.
The Week That Was: ... | Blog
It’s all in the latest edition of The Week that Was.
It was another intense week in healthcare headlines.
House of Representatives for a vote in just a few weeks.
The anti-vaccination movement is causing challenges not just in healthcare, but now in tech.
Employers wield enormous influence in deciding the care their employees receive – yet they aren’t always considered a core “stakeholder” in the healthcare debate.
You may have seen a lot of recent reporting on “loss of coverage” for Americans.
Prescription delivery services – like Hims, Roman and Kick – are popping up all over the place, prompting concerns about regulation.
Everyone seems to be talking about digital health, but what does that really look like in action?
Climate change is named a top 10 health threat and we’ve broken down the conundrum for pharma companies regarding activating on the issue.
In case you haven’t heard, it’s the New Year.
Drug makers aren’t the only ones under pressure for high costs.
Policymakers continue their focus on drug pricing and may also have eyes for changes to the Orphan Drug Act.
Our team kept an eye on a number of stories about opioid “pledges,” top-line data communications and, as always, drug pricing.
(Yeah, Weird Week) | Blog
Good morning, readers!
President Trump and HHS Secretary Azar gave a slightly delayed, much anticipated speech on the Administration’s Blueprint to lower drug prices.
The prevalence of these life threatening conditions is increasing and medical scientists can’t seem to figure out why.
From new hires to emerging partnerships, Apple's recent actions reveal increased focus on revolutionizing healthcare
Last week, Big Blue extended its maternity leave from 14 weeks of paid time off to up to 20 weeks.
Last week was the equivalent of editorial catnip for our team.
Medicine’s #MeToo Moment | Blog
What a week!